| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |